UB Paderborn / Katalog / Suche / in CDI

1 – 20 von 20

Sortiert nach

S40 Should genomic profiles be used to determine who should receive adjuvant chemotherapy?

Breast (Edinburgh), 2009, Vol.18, p.S17-S17

Albain, K.S

2009

Link zum Volltext

Verfügbarkeit prüfen

The 21-Gene Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer Treated on SWOG S8814

International journal of radiation oncology, biology, physics, 2016-10, Vol.96 (2), p.S146-S146

2016

Link zum Volltext

Verfügbarkeit prüfen

Chemotherapy (CT) decision in node-positive (N+), ER+, early breast cancer (EBC) after new ASCO Guideline – evidence for the 21-gene Recurrence Score (RS) assay

Breast (Edinburgh), 2017-03, Vol.32, p.S98-S98

2017

Link zum Volltext

Verfügbarkeit prüfen

187 INVITED Challenges and opportunities in the intergration of new and old treatments

European journal of cancer supplements, 2007, Vol.5 (4), p.49-49

Albain, K.S

2007

Link zum Volltext

Verfügbarkeit prüfen

Treatment Efficacy Score—continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials

Annals of oncology, 2022-08, Vol.33 (8), p.814-823

2022

Link zum Volltext

Verfügbarkeit prüfen

Patterns of Care in Malignant Pleural Mesothelioma at Academic Versus Non-Academic Centers

International journal of radiation oncology, biology, physics, 2017-10, Vol.99 (2), p.E438-E439

2017

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Stereotactic Body Radiation Therapy for Clinically Diagnosed Early-stage Lung Cancer: Early Analysis of Quality of Life

International journal of radiation oncology, biology, physics, 2020-11, Vol.108 (3), p.e218-e218

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Stereotactic Body Radiation Therapy for Clinically Diagnosed Early-Stage Lung Cancer: Early Analysis of Toxicity

International journal of radiation oncology, biology, physics, 2020-11, Vol.108 (3), p.e102-e102

2020

Link zum Volltext

Verfügbarkeit prüfen

P246 - Breast cancer-specific survival (BCSS) in patients (pts) with nodenegative (N0) and node-positive (N+) breast cancer (BC) guided by the 21-gene assay: a SEER-genomic real-world evidence study

Breast (Edinburgh), 2019-03, Vol.44, p.S100-S101

2019

Link zum Volltext

Verfügbarkeit prüfen

Breast cancer-specific survival (BCSS) in patients (pts) with nodenegative (N0) and node-positive (N+) breast cancer (BC) guided by the 21-gene assay: a SEER-genomic real-world evidence study

Breast (Edinburgh), 2019-03, Vol.44, p.S100-S101

2019

Link zum Volltext

Verfügbarkeit prüfen

P226 - Chemotherapy (CT) decision in node-positive (N+), ER+, early breast cancer (EBC) after new ASCO Guideline – evidence for the 21-gene Recurrence Score (RS) assay

Breast (Edinburgh), 2017-03, Vol.32, p.S98-S98

2017

Link zum Volltext

Verfügbarkeit prüfen

Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer

The pharmacogenomics journal, 2014-06, Vol.14 (3), p.241-247

2014

Link zum Volltext

Verfügbarkeit prüfen

Induction treatment before surgery for non-small cell lung cancer

Lung cancer, 2003-12, Vol.42 (2), p.9-14

2003

Link zum Volltext

Verfügbarkeit prüfen

108

International journal of radiation oncology, biology, physics, 2006-11, Vol.66 (3), p.S61-S62

2006

Link zum Volltext

Verfügbarkeit prüfen

108: Analysis of V20 and Radiation Pneumonitis on SWOG0023: A Phase III Trial of Concurrent Chemoradiation and Docetaxel Consolidation in Stage III Nonsmall Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2006, Vol.66 (3), p.S61-S62

2006

Link zum Volltext

Verfügbarkeit prüfen

O-192a SWOG 0023: A randomized phase III trial of cisplatin/etoposide(PE) plus radiation therapy followed by consolidation docetaxel then maintenance therapy with gefitinib or placebo in patients with locally advanced unresectable stage III non-small cell lung cancer (NSCLC)

Lung cancer (Amsterdam, Netherlands), 2005-07, Vol.49, p.S64-S64

2005

Link zum Volltext

Verfügbarkeit prüfen

Analysis of prognostic factors in southwest oncology group stage III non-small cell lung cancer trials requiring pre-treatment histological assessment of mediastinal lymph nodes

International journal of radiation oncology, biology, physics, 2002-10, Vol.54 (2), p.103-104

2002

Link zum Volltext

Verfügbarkeit prüfen

Randomized trial of chemoradiotherapy to 61 Gy [no S] versus chemoradiotherapy to 45 Gy followed by surgery [S] using cisplatin etoposide in stage IIIa non-small cell lung cancer (NSCLC): intergroup trial 0139, RTOG (9309)

International journal of radiation oncology, biology, physics, 2003-10, Vol.57 (2), p.S125-S126

2003

Link zum Volltext

Verfügbarkeit prüfen

Pathologic stage IIIb non-small cell lung cancer (NSCLC): Prolonged survival with consoloidation Docetaxel following concurrent chemoradiotherapy (SWOG 9504)

Lung cancer (Amsterdam, Netherlands), 2000-09, Vol.29 (1), p.92-93

2000

Link zum Volltext

Verfügbarkeit prüfen

Induction treatment for resectable non-small-cell lung cancer

Lung cancer (Amsterdam, Netherlands), 1997-06, Vol.17, p.S15-S18

1997

Link zum Volltext

Verfügbarkeit prüfen

1 – 20 von 20

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(18)

Publikationsform

Artikel
(20)

Sprache

Englisch
(20)

Erscheinungsjahr

n.n

Zeitschrift / Serie

International Journal Of Radiation Oncology, Biology, Physics
(8)
Breast
(5)
Lung Cancer
(4)
Annals Of Oncology
(1)
European Journal Of Cancer Supplements
(1)
The Pharmacogenomics Journal
(1)

1 weiteren anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

S40 Should genomic profiles be used to determine who should receive adjuvant chemotherapy?

The 21-Gene Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer Treated on SWOG S8814

Chemotherapy (CT) decision in node-positive (N+), ER+, early breast cancer (EBC) after new ASCO Guideline – evidence for the 21-gene Recurrence Score (RS) assay

187 INVITED Challenges and opportunities in the intergration of new and old treatments

Treatment Efficacy Score—continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials

Patterns of Care in Malignant Pleural Mesothelioma at Academic Versus Non-Academic Centers

Phase II Study of Stereotactic Body Radiation Therapy for Clinically Diagnosed Early-stage Lung Cancer: Early Analysis of Quality of Life

Phase II Study of Stereotactic Body Radiation Therapy for Clinically Diagnosed Early-Stage Lung Cancer: Early Analysis of Toxicity

P246 - Breast cancer-specific survival (BCSS) in patients (pts) with nodenegative (N0) and node-positive (N+) breast cancer (BC) guided by the 21-gene assay: a SEER-genomic real-world evidence study

Breast cancer-specific survival (BCSS) in patients (pts) with nodenegative (N0) and node-positive (N+) breast cancer (BC) guided by the 21-gene assay: a SEER-genomic real-world evidence study

P226 - Chemotherapy (CT) decision in node-positive (N+), ER+, early breast cancer (EBC) after new ASCO Guideline – evidence for the 21-gene Recurrence Score (RS) assay

Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer

Induction treatment before surgery for non-small cell lung cancer

108

108: Analysis of V20 and Radiation Pneumonitis on SWOG0023: A Phase III Trial of Concurrent Chemoradiation and Docetaxel Consolidation in Stage III Nonsmall Cell Lung Cancer

O-192a SWOG 0023: A randomized phase III trial of cisplatin/etoposide(PE) plus radiation therapy followed by consolidation docetaxel then maintenance therapy with gefitinib or placebo in patients with locally advanced unresectable stage III non-small cell lung cancer (NSCLC)

Analysis of prognostic factors in southwest oncology group stage III non-small cell lung cancer trials requiring pre-treatment histological assessment of mediastinal lymph nodes

Randomized trial of chemoradiotherapy to 61 Gy [no S] versus chemoradiotherapy to 45 Gy followed by surgery [S] using cisplatin etoposide in stage IIIa non-small cell lung cancer (NSCLC): intergroup trial 0139, RTOG (9309)

Pathologic stage IIIb non-small cell lung cancer (NSCLC): Prolonged survival with consoloidation Docetaxel following concurrent chemoradiotherapy (SWOG 9504)

Induction treatment for resectable non-small-cell lung cancer

Suchergebnisse filtern